Brainstorm Cell Therapeutics Inc. (BCLI) At $4.41 Forms Bottom; Shorts at REVIVE THERAPEUTICS LTD. ORDINARY SHARES (RVVTF) Lowered By 10%

Revive Therapeutics Ltd. (OTCMKTS:RVVTF) Logo

REVIVE THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:RVVTF) had a decrease of 10% in short interest. RVVTF’s SI was 900 shares in June as released by FINRA. Its down 10% from 1,000 shares previously. With 8,800 avg volume, 0 days are for REVIVE THERAPEUTICS LTD. ORDINARY SHARES (OTCMKTS:RVVTF)’s short sellers to cover RVVTF’s short positions. The stock decreased 0.84% or $0.00124 during the last trading session, reaching $0.14576. About 10,242 shares traded or 21.16% up from the average. Revive Therapeutics Ltd. (OTCMKTS:RVVTF) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Brainstorm Cell Therapeutics Inc. (BCLI) formed multiple bottom with $4.01 target or 9.00% below today’s $4.41 share price. Brainstorm Cell Therapeutics Inc. (BCLI) has $89.30M valuation. It closed at $4.41 lastly. It is down 14.11% since June 17, 2017 and is uptrending. It has outperformed by 1.54% the S&P500. Some Historical BCLI News: ; 08/03/2018 BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017; 12/03/2018 – BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair; 25/05/2018 – BrainStorm Cell Therapeutics Issues Statement on “Right to Try” Legislation; 30/03/2018 – CIRM: Stem Cell Roundup: Crafty Cancer, Fighting Viruses, and Brainstorm ALS Trial Expands to Canada; 09/03/2018 – BrainStorm Cell Therapeutics Short-Interest Ratio Up to 32 Days; 21/03/2018 – BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advis; 13/03/2018 – Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer; 01/05/2018 – BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference; 14/05/2018 – Brainstorm Cell Therptcs 1Q Loss/Shr 12c; 08/03/2018 – Brainstorm Cell Therptcs Yr Loss/Shr 26c

Analysts await Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings on August, 13. They expect $-0.14 EPS, down 133.33% or $0.08 from last year’s $-0.06 per share. After $-0.12 actual EPS reported by Brainstorm Cell Therapeutics Inc. for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.

Among 2 analysts covering Brainstorm Cell Therapeutics (NASDAQ:BCLI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Brainstorm Cell Therapeutics has $14 highest and $5.0 lowest target. $10’s average target is 126.76% above currents $4.41 stock price. Brainstorm Cell Therapeutics had 6 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Wednesday, August 16. The rating was maintained by Maxim Group with “Buy” on Friday, July 21. H.C. Wainwright initiated Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) on Tuesday, May 15 with “Buy” rating. On Wednesday, August 12 the stock rating was maintained by Maxim Group with “Buy”. The firm earned “Buy” rating on Tuesday, June 13 by Maxim Group. Maxim Group maintained Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) on Tuesday, December 22 with “Buy” rating.

Revive Therapeutics Ltd. focuses on the development and commercialization of various drugs in Canada. The company has market cap of $9.64 million. The firm develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. It currently has negative earnings. The Company’s product pipeline also includes REV-003, a tianeptine for treatment of Rett Syndrome; and REV-004, a bucillamine for the treatment of cystinurial, as well as REV-005 for the treatment of WilsonÂ’s disease, which are under various stages of development.